Abstract
The neuroendocrine effects of the 5-HT receptor agonist, sumatriptan (6 mg subcutaneously), were studied in 11 healthy male subjects using a placebo-controlled, cross-over design. Compared to placebo, sumatriptan significantly lowered levels of plasma prolactin but increased those of plasma growth hormone. There was no effect on plasma cortisol concentrations. The neuroendocrine effects of sumatriptan differ from those of previously described 5-HT-receptor agonists, and may be a consequence of selective activation of 5-HT1D or 5-HT1B receptors. However, the present data cannot exclude the possibility that the neuroendocrine changes reflect non-specific stress responses or changes in pituitary blood flow.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Anderson IM, Cowen PJ, Grahame-Smith DG (1990) The effect of gepirone on neuroendocrine function in humans. Psychopharmacology 100:498–503
Checkley SA (1980) Neuroendocrine tests of monoamine function in man: a review of basic theory and its application to the study of depressive illness. Psychol Med 10:35–53
Connor HE, Feniuk W (1992) Migraine, serotonin and sumatriptan. Vasc Med Rev 3:95–108
Cowen PJ (1992) Neuroendocrine measures of 5-HT receptor subtype function in depression. In: Bradley PB, Handley SL, Cooper SJ, Key BJ, Barnes NM, Coote JH (eds) Serotonin, CNS receptors and brain function. Pergamon Press, Oxford, pp 287–296
Cowen PJ, Anderson IM, Grahame-Smith DG (1990) Neuroendocrine effects of azapirones. J Clin Psychopharmacol 10:21S-25S
Cryer PE, Daughaday WH (1977) Growth hormone. In: Martini L, Besser GM (eds) Clinical neuroendocrinology. Academic Press, New York, pp 243–277
Dallas FA, Dixon CM, McCulloch RJ, Saynor DA (1989) The kinetics of14C-GR43175 in rat and dog. Cephalalgia 9 [Suppl 9]:53–56
Dechant KL, Clissold SP (1992) Sumatriptan: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 43:776–798
Eckland DJ, Entwisle SJ, Fowler PA, Thomas M, Lettis S, York M, Freedman PS (1992) The effects of sumatriptan, a 5-HT1-like agonist on pituitary adrenal function in healthy volunteers. Br J Clin Pharmacol 33:538P
Gartside SE, Ellis PM, Sharp T, Cowen PJ (1992) Selective 5-HT1A and 5-HT2 receptor-mediated adrenocorticotropin release in the rat: effect of repeated antidepressant treatments. Eur J Pharmacol 221:27–33
Gilbert F, Brazell C, Tricklebank MD, Stahl SM (1988) Activation of the 5-HT1A receptor subtype increases rat plasma ACTH concentration. Eur J Pharmacol 147:431–439
King BH, Brazell C, Dourish CT, Middlemiss DN (1989) MK-212 increases rat plasma ACTH concentration by activation of the 5-HT1C receptor subtype. Neurosci Lett 105:174–176
Lesch KP (1992) 5-HT1A receptor responsivity in anxiety disorders and depression. Prog Neuro Psychopharmacol Biol Psychiatry 15:723–733
Lowther S, De Paermentier FD, Crompton MR, Horton RW (1992) The distribution of 5-HT1D and 5-HT1E binding sites in human brain. Eur J Pharmacol 222:137–142
Meltzer HY, Nash JF (1988) Serotonin and mood: neuroendocrine aspects. In: Ganten D, Pfaff D (eds) Current topics in neuroendocrinology, Vol 8. Springer, Berlin Heidelberg New York, pp 183–210
Middlemiss DN, Bremer ME, Smith SM (1988) A pharmacological analysis of the 5-HT receptor mediating inhibition of 5-HT release in the guinea pig frontal cortex. Eur J Pharmacol 157:101–104
Montage, M, Calas A (1988) Serotonin and endocrinology — the pituitary. In: Osborne NN, Hamon M (eds) Neuronal serotonin Wiley, Chichester, pp 271–303
Oksenberg D, Marsters SA, O'Dowd BF, Jin H, Havlik S, Peroutka SJ, Ashkenazi A (1992) A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors. Nature 360:161–163
Peroutka SJ (1992) Molecular biology of 5-HT receptor subtypes. In: Bradley PB, Handley SL, Cooper SJ, Key BJ, Barnes NM, Coote JH (eds) Serotonin, CNS receptors and brain function. Pergamon, Oxford, pp 1–11
Peroutka SJ, McCarthy BG (1989) Sumatriptan (GR43175) interacts selectively with 5-HT1B and 5-HT1D binding sites. Eur J Pharmacol 163:133–136
Rolandi E, Franceschini R, Cataldi A, Barreca T (1992) Endocrine effects of sumatriptan. Lancet 339:1365
Schlicker E, Fink K, Gothert M, Hoyer D, Molderings G, Roschke I, Schoeffter P (1989) The pharmacological properties of presynaptic serotonin autoreceptors in pig brain cortex conform to the 5-HT1D receptor subtype. Naunyn-Schmiedeberg's Arch Pharmacol 340:45–51
Schoeffter P, Hoyer D (1989) How selective is GR43175? Interactions with functional 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors. Nauyn-Schmiedeberg's Arch Pharmacol 340:135–138
Sleight AJ, Cevenka A, Peroutka SJ (1990) In vivo effects of sumatriptan (GR43175) on extracellular levels of 5-HT in the guinea pig. Neuropharmacology 29:511–513
Tuomisto J, Mannisto P (1985) Neurotransmitter regulation of anterior pituitary hormones. Pharmacol Rev 37:249–332
Wilkinson LO, Middlemiss DN (1992) The autoregulation of 5-HT release from nerve terminals in vitro. In: Bradley PB, Handley SL, Cooper SJ, Key BJ, Barnes NM, Coote JH (eds) Serotonin, CNS receptors and brain function. Pergamon, Oxford, pp 1–11
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Herdman, J.R.E., Delva, N.J., Hockney, R.E. et al. Neuroendocrine effects of sumatriptan. Psychopharmacology 113, 561–564 (1994). https://doi.org/10.1007/BF02245240
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02245240